# Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

> **NCT03052933** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chonnam National University Hospital** · enrollment: 28 (actual)

## Conditions studied

- Mature T-Cell and NK-Cell Neoplasm

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03052933
- **Lead sponsor:** Chonnam National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-06-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03052933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03052933, "Copanlisib and Gemcitabine in Relapsed/Refractory PTCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03052933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*